A practical reference on solid-phase synthesis: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-19. Anything still debated is marked as such rather than presented as settled.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
=== 2020s === In 2020, Sonic unveiled a new drive-in design with an updated, wider layout for car docks and the drive-thru lane, a new kitchen layout built for efficiency, and an aesthetic makeover. By March 2020, all locations indefinitely suspended patio dining due to COVID-19, but continued to serve take-away and pickup customers.
CA7 is a small-molecule oxytocin receptor agonist. It is said to be potent as an agonist of the oxytocin receptor and to show considerable selectivity over the vasopressin V1A receptor, where it displayed no functional activity. However, the exact affinity and activity values at these receptors do not appear to have been disclosed. The chemical synthesis of CA7 has been described. Along with its close analogue WJ0679, CA7 has the smallest chemical structure known for an oxytocin receptor agonist, with WJ0679 having about 60% of the molecular weight of LIT-001 and both WJ0679 and CA7 lacking LIT-001's tail component. Many analogues of WJ0679 and CA7 have been described. CA7 was first described in the scientific literature by a group including Michael Kassiou, Michael Bowen, Iain McGregor, and others at the University of Sydney in 2018. This group has founded a startup pharmaceutical company called Kinoxis Therapeutics and is developing small-molecule oxytocin-related drugs like KNX-100 and the KNX-200 series for potential medical use as of the 2020s.
It may be an advantage to know that a man can travel 520 miles in 138 hours, and manage to live through a week with an infinitesimal amount of rest, though we fail to perceive that anyone could possibly be placed in a position where his ability in this respect would be of any use to him [and] what is to be gained by a constant repetition of the fact. The event proved popular, however, with 20,000 spectators attending each day. Encouraged, the promoters developed the idea and soon held similar races for cyclists.
The SADC has specifically emphasised the importance of combating non-traditional maritime threats as part of the 2050 Integrated Maritime Strategy. The Bay of Bengal Initiative for Multi-Sectoral Technical and Economic Cooperation (BIMSTEC), has enabled the states within the Bay of Bengal to create greater maritime security through collaboration between countries. Furthermore, BIMSTEC has launched a Convention on Cooperation in Combating International Terrorism, Organised Crime and Illicit Drug Trafficking. This facilitates regional cooperation specific to the illicit drug trade, and provides the region with the foundations to develop their response further. The existing regional and individual responses by states have, in practice, been limited to seizure-based responses. This is due to gaps in the current legal infrastructure, which prevent effective prosecution of smugglers following drug seizures. Huge drug seizures have been made by both the Combined Maritime Forces (CMF) and the Combined task force (CTF), such as when the CTF successfully seized 6.2 tonnes of hashish over two days. However, gaps in the current laws prevent further action. One such example is Article 110 of the UNSC Law of the Sea Convention 1982, which does not include a suspicion of drug smuggling as a legitimate reason to board a vessel without gaining permission from the ship’s flagged country. This has decreased the amount of possible seizures, and gaining permission to board vessels is complicated by insufficient regional cooperation within the criminal justice system.
Sources: en.wikipedia.org
== Bibliography == Cowie, J. M. G. (John McKenzie Grant) (1991). Polymers: chemistry and physics of modern materials. Glasgow: Blackie. ISBN 978-0-412-03121-2. Hall, Christopher (1989). Polymer materials (PDF) (2nd ed.). London; New York: Macmillan. ISBN 978-0-333-46379-6. Rudin, Alfred (1982). The elements of polymer science and engineering. Academic Press. ISBN 978-0-12-601680-2. Wright, David C. (2001). Environmental Stress Cracking of Plastics. RAPRA. ISBN 978-1-85957-064-7.
The national flower of Belize is the black orchid (Prosthechea cochleata, also known as Encyclia cochleata). The national tree is the mahogany tree (Swietenia macrophylla), which inspired the national motto Sub umbra floreo, which means "Under the shade I flourish". The national ground-dwelling animal is the Baird's tapir and the national bird is the keel-billed toucan.
In late 2005, researchers at the University of Melbourne speculated that the perentie (Varanus giganteus), other species of monitors, and agamids may be somewhat venomous. The team believes that the immediate effects of bites from these lizards were caused by mild envenomation. Bites on human digits by a lace monitor (V. varius), a Komodo dragon, and a spotted tree monitor (V. timorensis) all produced similar effects: rapid swelling, localised disruption of blood clotting, and shooting pain up to the elbow, with some symptoms lasting for several hours. In 2009, the same researchers published further evidence demonstrating that Komodo dragons possess a venomous bite. MRI scans of a preserved skull showed the presence of two glands in the lower jaw. The researchers extracted one of these glands from the head of a terminally ill dragon in the Singapore Zoological Gardens, and found it secreted several different toxic proteins. The known functions of these proteins include inhibition of blood clotting, lowering of blood pressure, muscle paralysis, and the induction of hypothermia, leading to shock and loss of consciousness in envenomated prey. As a result of the discovery, the previous theory that bacteria were responsible for the deaths of Komodo victims was disputed.
==== JPT2 ==== The 20kDa Jupiter microtubule-associated homolog 2 (JPT2) (also known as HN1L) was the first accessory protein to be published as a mediator of NAADP-dependent Ca2+ release. Both studies exploited the same novel 'clickable' NAADP photoprobe, but regardless of the different blood cell types, the authors converged on the same molecular partner (although the studies differ in the channel that is activated). JPT2 binds [32P]NAADP with selectivity over a spectrum of different nucleotides. In Ca2+-release studies, NAADP-dependent signals were inhibited by siRNA knockdown of JPT2, but not of its homolog, JPT1, attesting to isoform specificity. Interestingly, JPT2 exhibited a preferential interaction with TPC1 over TPC2. Given that TPCs are known to drive pathogen uptake into cells, it was striking that uptake of a Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pseudovirus was likewise reduced by JPT2 gene silencing.
=== Covalent peptide tags === Isopeptag, a peptide which binds covalently to pilin-C protein (TDKDMTITFTNKKDAE) SpyTag, a peptide which binds covalently to SpyCatcher protein (AHIVMVDAYKPTK) SnoopTag, a peptide which binds covalently to SnoopCatcher protein (KLGDIEFIKVNK). A second generation, SnoopTagJr, was also developed to bind to either SnoopCatcher or DogTag (mediated by SnoopLigase) (KLGSIEFIKVNK) DogTag, a peptide which covalently binds to DogCatcher (DIPATYEFTDGKHYITNEPIPPK) and can react as an internal tag in loops of proteins. DogTag can also covalently bind to SnoopTagJr, mediated by SnoopLigase. SdyTag, a peptide which binds covalently to SdyCatcher protein (DPIVMIDNDKPIT). SdyTag/SdyCatcher has a kinetic-dependent cross-reactivity with SpyTag/SpyCatcher.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.